title: Remestemcel-L for acute graft-versus-host disease therapy.
abstract: BACKGROUND
  Remestemcel-L (Prochymal®, Osiris) is an off-the-shelf adult mesenchymal stromal cell product that has been applied to acute graft-versus-host disease (aGvHD) for its immunomodulatory properties.
  
  
  METHODS
  This article discusses preclinical and clinical studies supporting the use of remestemcel-L in aGvHD as well as the current regulatory status. This information was based upon a PubMed and Internet search.
  
  
  CONCLUSIONS
  Phase II studies suggest remestemcel-L may have clinical activity in aGvHD and confirm tolerability. However, these results must be interpreted cautiously with any use of remestemcel-L optimally occurring in the context of a clinical trial. Further clarity will be obtained when the results of a completed Phase III study are published. There is a small market for remestemcel-L in aGvHD. A possible future scenario is that a more prevalent indication is found and remestemcel-L is approved for that indication, but use continues for aGvHD.
authors.affiliation: Roswell Park Cancer Institute, Department of Medicine, BMT Program , Elm and Carlton Streets, Buffalo, NY 14263 , USA +1 716 845 8412 ; philip.mccarthy@roswellpark.org.
authors.forename: George L
authors.initials: GL
authors.lastname: Chen
authors.forename: Pamela
authors.initials: P
authors.lastname: Paplham
authors.forename: Philip L
authors.initials: PL
authors.lastname: McCarthy
mesh_terms: D017322:Clinical Trials, Phase II as Topic; D017277:Drug Approval; D005938:Glucocorticoids / Q000737:chemistry; D006086:Graft vs Host Disease / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007107:Immune System; D007155:Immunologic Factors / Q000737:chemistry; D007166:Immunosuppressive Agents / Q000737:chemistry; D059630:Mesenchymal Stem Cells / Q000166:cytology*; D016032:Randomized Controlled Trials as Topic; D014020:Tissue Extracts / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D005938:Glucocorticoids; D007155:Immunologic Factors; D007166:Immunosuppressive Agents; D014020:Tissue Extracts